	US 12,280,102 B2
	Alphavirus replicon encoding chimeric SARS-CoV-2 receptor binding domains
Wataru Akahata, Kensington, MD (US); Jonathan F. Smith, Redwood City, CA (US); and Ryuji Ueno, Easton, MD (US)
Assigned to VLP Therapeutics, Inc., Wilmington, DE (US)
Filed by VLP Therapeutics, Inc., Wilmington, DE (US)
Filed on Apr. 16, 2021, as Appl. No. 17/232,666.
Claims priority of provisional application 63/088,723, filed on Oct. 7, 2020.
Claims priority of provisional application 63/050,442, filed on Jul. 10, 2020.
Claims priority of provisional application 63/011,561, filed on Apr. 17, 2020.
Prior Publication US 2021/0322541 A1, Oct. 21, 2021
Int. Cl. A61K 39/215 (2006.01); C07K 14/165 (2006.01); C07K 14/18 (2006.01)

CPC A61K 39/215 (2013.01) [C07K 14/165 (2013.01); C07K 14/1808 (2013.01); C07K 2319/02 (2013.01); C07K 2319/03 (2013.01); C12N 2770/20034 (2013.01); C12N 2770/36141 (2013.01)]

16 Claims

1. An isolated polynucleotide, which encodes alphavirus non-structural proteins nsP1, nsP2, nsP3, and nsP4 and

a polypeptide comprising a receptor binding domain (RBD) of an S1 subunit in a spike protein of a SARS-CoV2 fused to a transmembrane domain and optionally to a signal sequence,

wherein the alphavirus is Venezuelan Equine Encephalitis Virus or Chikungunya virus, and

wherein the transmembrane domain is heterologous to the SARS-CoV-2.